BIOCRYST PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Net of Tax
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Other Comprehensive Income (Loss), Net of Tax of -$566.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2024-05-07
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was -$566.00K, a 201.25% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was $110.00K.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-06-30 was $105.00K.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-03-31 was $559.00K, a 6111.11% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $1.31M.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$151.00K, a 186.78% decline from fiscal 2021.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2021 was $174.00K.
- BIOCRYST PHARMACEUTICALS, INC. other comprehensive income (loss), net of tax for fiscal 2020 was -$36.00K, a 110.71% decline from fiscal 2019.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$566.00K 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $1.31M 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $110.00K 10-Q · filed 2023-11-08 | $215.00K derived: sum of 2 quarters · filed 2023-11-08 | $774.00K derived: sum of 3 quarters · filed 2024-05-07 | |
| 2023-06-30 | $105.00K 10-Q · filed 2023-11-08 | $664.00K derived: sum of 2 quarters · filed 2024-05-07 | ||
| 2023-03-31 | $559.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$151.00K 10-K · filed 2024-02-27 | |||
| 2022-09-30 | -$113.00K 10-Q · filed 2023-11-08 | -$284.00K derived: sum of 2 quarters · filed 2023-11-08 | -$275.00K derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | -$171.00K 10-Q · filed 2023-11-08 | -$162.00K derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $9.00K 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $174.00K 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $27.00K 10-Q · filed 2022-11-04 | -$68.00K derived: sum of 2 quarters · filed 2022-11-04 | $111.00K derived: sum of 3 quarters · filed 2022-11-04 | |
| 2021-06-30 | -$95.00K 10-Q · filed 2022-11-04 | $84.00K derived: sum of 2 quarters · filed 2022-11-04 | ||
| 2021-03-31 | $179.00K 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | -$36.00K 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $6.00K 10-Q · filed 2021-11-04 | -$5.00K derived: sum of 2 quarters · filed 2021-11-04 | -$30.00K derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | -$11.00K 10-Q · filed 2021-11-04 | -$36.00K derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | -$25.00K 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $336.00K 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $19.00K 10-Q · filed 2020-11-06 | $149.00K derived: sum of 2 quarters · filed 2020-11-06 | $357.00K derived: sum of 3 quarters · filed 2020-11-06 | |
| 2019-06-30 | $130.00K 10-Q · filed 2020-11-06 | $338.00K derived: sum of 2 quarters · filed 2020-11-06 | ||
| 2019-03-31 | $208.00K 10-Q · filed 2020-11-06 | |||
| 2018-12-31 | -$54.00K 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $42.00K 10-Q · filed 2019-11-08 | $66.00K derived: sum of 2 quarters · filed 2019-11-08 | -$167.00K derived: sum of 3 quarters · filed 2019-11-08 | |
| 2018-06-30 | $24.00K 10-Q · filed 2019-11-08 | -$209.00K derived: sum of 2 quarters · filed 2019-11-08 | ||
| 2018-03-31 | -$233.00K 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | -$231.00K 10-K · filed 2020-03-13 | |||
| 2016-12-31 | $194.00K 10-K · filed 2019-03-14 | |||
| 2015-12-31 | -$76.00K 10-K · filed 2018-03-12 | |||
| 2014-12-31 | -$134.00K 10-K · filed 2017-02-27 | |||
| 2013-12-31 | -$23.00K 10-K · filed 2016-02-26 | |||
| 2012-12-31 | -$13.00K 10-K · filed 2015-03-02 | |||
| 2011-12-31 | -$65.00K 10-K · filed 2014-03-10 | |||
| 2010-12-31 | $131.00K 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |